THE OLD BOTTLENECK
For decades, genetic engineering meant moving one gene at a time. A useful metabolic pathway needs ten or twenty enzymes working in sequence — assembling that much DNA reliably was the limit. Modern fragment assembly (Gibson, Golden Gate, yeast homologous recombination) lets researchers stitch entire pathways in a single step.
WHY YEAST AND E. COLI
Saccharomyces cerevisiae and Escherichia coli are the workhorses because they grow fast, tolerate foreign DNA, and have a century of fermentation engineering behind them. Brewing infrastructure scales directly: a microbe that makes insulin uses the same stainless-steel tanks that make beer.
THE LANDMARK CASE
Artemisinin, the frontline malaria drug, is extracted from sweet wormwood — supply was volatile and prices swung wildly. Jay Keasling's lab spent over a decade engineering yeast to produce artemisinic acid; Sanofi industrialized it in 2013. It remains the canonical proof that a plant-derived medicine can be moved into a fermenter.
THE METABOLIC TAX
Every gram of product the cell makes is a gram it doesn't use to grow. Engineered microbes are tuned to divert carbon flux from biomass into the target molecule — too aggressive and the cells die; too gentle and yields don't pay. This balancing is why most pathways take years to optimize even after assembly is solved.
THE REGULATORY FRONTIER
Contained fermentation is well-regulated globally — FDA, EMA, and equivalents have decades of precedent for microbially-produced drugs. The harder questions arrive with environmental release: engineered microbes designed to fix nitrogen in soil, degrade plastic in oceans, or modify gut microbiomes. No country has a settled framework for these.